LGMN and Parkinson disease: Legumain has been suggested to also have a key role in the pathogenesis of Parkinson’s disease (PD) due to the cleavage of α-synuclein (Table 1), triggering the aggregation of the cleavage products in Lewy bodies, the neurotoxicity of dopaminergic neurons, and movement disorders [30].